Cantor downgrades Supernus on ‘disappointing’ depression study
Cantor Fitzgerald last night downgraded Supernus (SUPN) to Neutral from Overweight with a price target of $36, down from $57. The firm cites ...
Supernus' depression treatment fails mid-stage trial, shares plunge
Supernus Pharmaceuticals said on Tuesday its depression treatment trial failed to meet the main goal of reduction in depressive symptoms, sending its shares down 20% aftermarket. The company said the ...
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS ...
Neurology Advisor5d
FDA Approves Wearable Infusion Device for Advanced Parkinson Disease
The US Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in ...